Gilead pays $100M for first dibs on all Assembly Bio assets, bolting antiviral engine to its R&D group

Gilead Sciences wants first dibs on all Assembly Biosciences’ programs. Rather than buy the viral disease biotech outright, Gilead is paying $100 million upfront for opt-in rights on all Assembly Bio’s current and future programs.